The angiogenin gene has been linked to amyotrophic lateral sclerosis (ALS) for years, but a study in the Annals of Neurology adds a new wrinkle: These variants are just as likely to cause Parkinson’s disease. The authors of the international, multisite report—posted online August 17—are not sure what causes one person with abnormal angiogenin to suffer motor neuron disease, while others develop parkinsonism. Angiogenin is a neuroprotective factor, and based on this research, it might someday be a treatment not only for ALS, but also for Parkinson’s.
Angiogenin variants are so rare that not all studies have shown the gene associated with ALS, said Amelie Gubitz, program director for neurodegeneration at the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland. It is one of those risk factors that still had a question mark, she said. And since it is a risk factor that does not always cause disease, the fact that some healthy people possess angiogenin mutations has added further uncertainty to the gene’s role in neurodegeneration (see ARF related news story on Greenway et al., 2006; reviewed in Schymick et al., 2007). The new study, she said, helps clinch the angiogenin ALS link even as it expands the gene’s influence to Parkinson’s.
First author Michael van Es and senior author Leonard van den Berg, both at the University Medical Center Utrecht, The Netherlands, previously reported on a family in which several members carried an angiogenin mutation (van Es et al., 2009). Many, but not all, members with the angiogenin variant developed ALS. But one person in the pedigree was initially diagnosed with Parkinson’s disease. Other data have also linked ALS and Parkinson’s. For example, motor neuron disease and parkinsonism coincide in a condition unique to the Chamorro people of Guam (Hirano et al., 1966). And family members of people with ALS are at higher-than-normal risk for Parkinson’s (Majoor-Krakauer et al., 1994).
Intrigued, the researchers screened people with Parkinson’s for angiogenin mutations and found variants in the gene in approximately 1 percent of them. Co-senior author John Landers, of the University of Massachusetts Medical School in Worcester, had a similar idea. The groups joined forces, along with co-senior author Bart van de Warrenburg of the Radboud University Nijmegen Medical Center in The Netherlands, to perform the largest, and therefore best study possible, van Es told ARF in an e-mail. The researchers teamed with 52 other scientists across Europe and the U.S. to amass angiogenin sequences from both previously published studies and from new subjects. In total, the scientists analyzed the gene from 3,146 people with Parkinson’s, 6.471 with ALS, and 7,688 healthy control subjects.
Given the rarity of angiogenin variants, finding them required such a large collaboration, Gubitz said. Even among people with PD or ALS, angiogenin variants showed up in fewer than half a percent of participants. The team identified 27 angiogenin mutations that were found more often in people with neurodegeneration than in control participants. Compared to control subjects, people with ALS were more than nine times as likely to have an angiogenin mutation; those with Parkinson’s were nearly sevenfold more likely to carry an angiogenin variant.
Angiogenin mutations are found in nearly equal frequencies in ALS and PD patients, with comparable odds ratios, van Es wrote. So I do not think angiogenin mutations are more relevant to one disease or the other. He suspects that additional, unknown genetic factors might sway a person toward ALS or Parkinson’s. Environmental risks could also contribute, Gubitz suggested.
Angiogenin is not the first genetic risk factor to cross the borders between neurodegenerative diseases. For example, tau is linked to frontotemporal dementia as well as Parkinson’s (Subramanian et al., 2008). And an excess of genetic repeats in ataxin-2 can appear in either ALS or spinocerebellar ataxia (see ARF related news story on Elden et al., 2010), and may contribute to Parkinson’s as well (Payami et al., 2003).
Perhaps there are some shared cellular disease pathways that we could exploit in research and therapies, Gubitz suggested. Angiogenin protects neurons by blocking apoptosis. The variants tend to cause loss of function, van Es wrote, making cells more susceptible to programmed cell death (Wu et al., 2007; Subramanian, 2008). Could replacing angiogenin fix the problem? Researchers such as study co-author Guo-fu Hu, of Tufts Medical Center in Boston, are already testing the effects of angiogenin treatment in a mouse model of ALS (see ARF related news story on Li et al., 2011; also Kieran et al., 2008).
Van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, Groen EJ, Schulte C, Blauw HM, Koppers M, Diekstra FP, Fumoto K, LeClerc AL, Keagle P, Bloem BR, Scheffer H, van Nuenen BF, van Blitterswijk M, van Rheenen W, Wills AM, Lowe PP, Hu G, Yu W, Kishikawa H, Wu D, Folkerth RD, Mariani C, Goldwurm S, Pezzoli G, Van Damme P, Lemmens R, Dahlberg C, Birve A, Fernandez-Santiago R, Waibel S, Klein C, Weber M, van der Kooi AJ, de Visser M, Verbaan D, van Hilten JJ, Heutink P, Hennekam EA, Cuppen E, Berg D, Brown RH Jr., Silani V, Gasser T, Ludolph AC, Robberecht W, Ophoff RA, Veldink JH, Pasterkamp RJ, de Bakker PI, Landers JE, van de Warrenburg BP, van den Berg LH. Angiogenin variants in Parkinson’s disease and amyotrophic lateral sclerosis. 2011. Abstract
To view commentaries, primary articles and linked stories, go to the original posting on Alzforum.org here.
Copyright © 1996–2017 Biomedical Research Forum, LLC. All Rights Reserved.Share this: